| Characteristics . | Total . | Planning study (selected at random) . |
|---|---|---|
| Number | 30 | 20 |
| Age, median (range) | 69 (28–90) | 67 (28–82) |
| Sex, male/female | 14/16 | 9/11 |
| Tumor site | ||
| Nasal/maxillary/ethmoid sinus/sublingual·parotid·submandibular gland/others | 11/8/2/6/3 | 8/5/2/3/2 |
| Pathology | ||
| Melanoma/adenocarcinoma/olfactory neuroblastoma/adenoid cystic carcinoma | 9/13/1/7 | 8/8/1/3 |
| Skull base involvement (yes/no) | 16/14 | 12/8 |
| Skin involvement (yes/no) | 5/25 | 4/16 |
| GTV (ml), median (range) | 43.2 (10.0–181.5) | 37.9 (10.0–135.4) |
| CTV (ml), median (range) | 92.2 (23.0–226.0) | 72.7 (23.0–197.2) |
| PTV (ml), median (range) | 130.8 (37.0–334.3) | 116.0 (37.0–300.3) |
| T1/T2/T3/T4 | 1/6/2/21 | 1/4/0/16 |
| N1/N2 | 5/2 | 3/2 |
| Dose fractionation 70.2 GyE/26 Fr/60.8 GyE/16 Fr | 21/9 | 12/8 |
| Characteristics . | Total . | Planning study (selected at random) . |
|---|---|---|
| Number | 30 | 20 |
| Age, median (range) | 69 (28–90) | 67 (28–82) |
| Sex, male/female | 14/16 | 9/11 |
| Tumor site | ||
| Nasal/maxillary/ethmoid sinus/sublingual·parotid·submandibular gland/others | 11/8/2/6/3 | 8/5/2/3/2 |
| Pathology | ||
| Melanoma/adenocarcinoma/olfactory neuroblastoma/adenoid cystic carcinoma | 9/13/1/7 | 8/8/1/3 |
| Skull base involvement (yes/no) | 16/14 | 12/8 |
| Skin involvement (yes/no) | 5/25 | 4/16 |
| GTV (ml), median (range) | 43.2 (10.0–181.5) | 37.9 (10.0–135.4) |
| CTV (ml), median (range) | 92.2 (23.0–226.0) | 72.7 (23.0–197.2) |
| PTV (ml), median (range) | 130.8 (37.0–334.3) | 116.0 (37.0–300.3) |
| T1/T2/T3/T4 | 1/6/2/21 | 1/4/0/16 |
| N1/N2 | 5/2 | 3/2 |
| Dose fractionation 70.2 GyE/26 Fr/60.8 GyE/16 Fr | 21/9 | 12/8 |
GTV = gross tumor volume, CTV = clinical target volume, PTV = planning target volume, GyE = Gray equivalent, Fr = fraction.
| Characteristics . | Total . | Planning study (selected at random) . |
|---|---|---|
| Number | 30 | 20 |
| Age, median (range) | 69 (28–90) | 67 (28–82) |
| Sex, male/female | 14/16 | 9/11 |
| Tumor site | ||
| Nasal/maxillary/ethmoid sinus/sublingual·parotid·submandibular gland/others | 11/8/2/6/3 | 8/5/2/3/2 |
| Pathology | ||
| Melanoma/adenocarcinoma/olfactory neuroblastoma/adenoid cystic carcinoma | 9/13/1/7 | 8/8/1/3 |
| Skull base involvement (yes/no) | 16/14 | 12/8 |
| Skin involvement (yes/no) | 5/25 | 4/16 |
| GTV (ml), median (range) | 43.2 (10.0–181.5) | 37.9 (10.0–135.4) |
| CTV (ml), median (range) | 92.2 (23.0–226.0) | 72.7 (23.0–197.2) |
| PTV (ml), median (range) | 130.8 (37.0–334.3) | 116.0 (37.0–300.3) |
| T1/T2/T3/T4 | 1/6/2/21 | 1/4/0/16 |
| N1/N2 | 5/2 | 3/2 |
| Dose fractionation 70.2 GyE/26 Fr/60.8 GyE/16 Fr | 21/9 | 12/8 |
| Characteristics . | Total . | Planning study (selected at random) . |
|---|---|---|
| Number | 30 | 20 |
| Age, median (range) | 69 (28–90) | 67 (28–82) |
| Sex, male/female | 14/16 | 9/11 |
| Tumor site | ||
| Nasal/maxillary/ethmoid sinus/sublingual·parotid·submandibular gland/others | 11/8/2/6/3 | 8/5/2/3/2 |
| Pathology | ||
| Melanoma/adenocarcinoma/olfactory neuroblastoma/adenoid cystic carcinoma | 9/13/1/7 | 8/8/1/3 |
| Skull base involvement (yes/no) | 16/14 | 12/8 |
| Skin involvement (yes/no) | 5/25 | 4/16 |
| GTV (ml), median (range) | 43.2 (10.0–181.5) | 37.9 (10.0–135.4) |
| CTV (ml), median (range) | 92.2 (23.0–226.0) | 72.7 (23.0–197.2) |
| PTV (ml), median (range) | 130.8 (37.0–334.3) | 116.0 (37.0–300.3) |
| T1/T2/T3/T4 | 1/6/2/21 | 1/4/0/16 |
| N1/N2 | 5/2 | 3/2 |
| Dose fractionation 70.2 GyE/26 Fr/60.8 GyE/16 Fr | 21/9 | 12/8 |
GTV = gross tumor volume, CTV = clinical target volume, PTV = planning target volume, GyE = Gray equivalent, Fr = fraction.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
